Abstract | BACKGROUND: Dipeptidyl peptidase-4 inhibitors (DPP-4is) improve glucose control in patients with type 2 diabetes mellitus (DM); however, only few studies were properly designed to evaluate their cardiovascular (CV) effects. The purpose of this study was to assess the impact of DPP-4i treatment on CV morbidity and mortality. METHODS: Randomized clinical trials enrolling more than 200 patients, comparing DPP-4 versus placebo or active treatments in patients with DM and reporting at least one event among all-cause and CV mortality, myocardial infarction (MI), stroke and new onset of heart failure (HF) were included in the analysis. RESULTS: Ninety-four trials enrolling 85,224 patients (median follow-up=29weeks) were included in the analysis. Compared to control, treatment with DPP-4i did not affect all-cause and CV mortality, as well as stroke, in the short and long terms (< and >=29weeks, respectively). DPP-4i reduced the risk of MI in the short (RR: 0.584 [95% CI: 0.361 to 0.943]; p=0.028), but not in the long term. Additionally, long-term treatment with DPP-4 was associated with a 15.8% increased risk of HF (RR: 1.158 [CI: 1.011 to 1.326]; p=0.034). No heterogeneity among studies or publication bias was detected. CONCLUSIONS: DPP4is do not affect all cause- and CV-mortality and stroke in diabetic patients; the reduction in MI observed with short-term treatment does not persist in the long term. Long-term use of DPP-4i in diabetic patients is associated with increased risk of HF.
|
Authors | Gianluigi Savarese, Pasquale Perrone-Filardi, Carmen D'Amore, Cristiana Vitale, Bruno Trimarco, Luca Pani, Giuseppe M C Rosano |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 181
Pg. 239-44
(Feb 15 2015)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 25528528
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
|
Topics |
- Cardiovascular Diseases
(chemically induced, diagnosis, epidemiology)
- Diabetes Mellitus, Type 2
(diagnosis, drug therapy, epidemiology)
- Dipeptidyl-Peptidase IV Inhibitors
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Humans
- Randomized Controlled Trials as Topic
(methods)
- Treatment Outcome
|